Abstract 4134778: Myocardial Recovery and Survival after Weaning of Left Ventricular Assist Device Therapy in Patients with Toxic and non-Toxic Cardiomyopathy, A Canadian Experience

Authors: Jean-Simon Lalancette, David Belzile, Alexandre Cinq-Mars, Sacha-Michelle Dubois-Senechal, Sylvain Lemay, Goran Rimac, Pierre Yves Turgeon, Joelle Morin, Christine Bourgault, Marie-Helene Leblanc, Celine Dupuis, Eric Charbonneau, Maxime Laflamme, mathieu bernier, Alexander Beaulieu-Shearer, Mario Senechal

Published: 2024-11-13

DOI: 10.1161/circ.150.suppl_1.4134778

Source: Full article

---

Abstract

Left ventricular assist devices (LVAD) are increasingly used in refractory heart failure, mainly as a bridge to transplant or as destination therapy. LVAD unloading of the left ventricle (LV) can also promote myocardial recovery leading to improvement of the LV systolic function, allowing LVAD explantation. However, parameters associated with LVAD weaning and long-term outcomes are not well documented. The aim of this study was to assess the clinical and echocardiographic characteristics of weaned patients and to evaluate their event-free survival post-explantation.